Vivid News 24: On Thursday, Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh unveiled the nasal Covid vaccine iNCOVACC from Bharat Biotech. It is the first nasal SARS-CoV-2 vaccine available in the country.
A native nasal vaccine will cost Rs 325 per shot for government purchases and Rs 800 per shot for private vaccination facilities, according to a December announcement from Bharat Biotech. The chairman and managing director of Bharat Biotech, Dr. Krishna Ella, has referred to the intranasal vaccination as a “global game changer.”
“We are happy to announce the clearance of iNCOVACC, a ground-breaking development in intranasal vaccination technology and delivery strategies. Despite the low demand for Covid-19 vaccines, we have been developing intranasal vaccines to keep our platform technologies up to date and ready for any new infectious diseases in the future.
The Washington University in St. Louis collaborated in the creation of the nasal vaccination as well as its preclinical efficacy testing. Bharat Biotech participated performed preclinical safety assessment, large-scale manufacturing scale-up, formulation, and delivery device development, as well as human clinical trials.
The clinical trials and product development were financed by the Indian government through the Covid Suraksha program of the Department of Biotechnology.
How does the nasal vaccine work?
A nasal vaccine “stimulates a wide immune response neutralizing IgG, mucosal IgA, and T cell responses and produces an immunological response at the site of infection (in the nasal mucosa) important for inhibiting both infection and transmission of Covid-19,” according to the website of Bharat Biotech.
Because BBV154 is an intranasal vaccine, it may cause the upper respiratory tract to develop local antibodies, which may have the potential to lessen infection and transmission.